Chief Scientific Officer of Zymeworks
Dr. Moore joined Zymeworks as CSO in July 2022 bringing over 25 years of US-based experience in biologics drug discovery and development in biotechnology research. His career efforts have led to the discovery and development of a range of FDA-approved and clinical-stage biologics for patients including those licensed for treatment of cancer and autoimmune conditions. Prior to Zymeworks, he led research and translation units at MacroGenics, culminating in the clinical development of > 15 novel therapeutic-based antibodies across various cancer types and autoimmune indications. Dr. Moore began his career at Human Genome Sciences (HGS) where he led various genomic-based target discovery programs including efforts that led to the discovery of BLyS, leading to development of Benlysta for the treatment of lupus. Dr. Moore received a PhD from the University of Glasgow, performed post-doctoral work at the Roche Institute of Molecular Biology, and holds a degree in Biotechnology from the University of Strathclyde. He has an extensive research record co-authoring over 80 peer-reviewed manuscripts and is a named co-inventor on over 50 issued US patents.